Notice ID: 1cd72a2626531c284ee6d1d8d77e88d6Combined Synopsis/Solicitation
Mixed Gender Human Liver Microsomes for NCATS Tox21 program
Archived on September 3, 2019. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 11:00 AM UTC−05:00
- Posted
- August 12, 2019
- Notice type
- Combined Synopsis/Solicitation
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
Notice details
- Place of performance
- 9800 Medical Center Drive, Rockville, MD, 20850
- PSC
- 99: MISCELLANEOUS
- Last updated
- Dec 6, 2025
Identifiers
- Solicitation number
- 75N95019Q00306
- Notice ID
- 1cd72a2626531c284ee6d1d8d77e88d6
Description
NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: Mixed Gender Human Liver Microsomes for NCATS Tox21 program (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95019Q00306 and the solicitation is issued as an request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), NIDA Office of Acquisitions - NCATS Section, on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Xenotech, LLC, 1101 W Cambridge Circle Drive, Kansas City, KS 66102-1311 for a reagent named "Mixed Gender Human Liver Microsomes". This acquisition is conducted as non-competitive for a commercial item or service and is conducted under the authority of the FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items and 13.501 Special documentation requirements and the authority of 41 U.S.C. 1901 and the FAR Subpart 13.106-1(b) Soliciting from a single source. Pursuant to FAR Subpart 13.501 (a) (1) (iv) the rationale for the brand name justification is that a reagent from Xenotech, LLC was previously optimized and tested for viability. Variables cannot be changed at this point without jeopardizing the continuity of science. In addition, changing variables would cause unnecessary expense for the government. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2019-02, dated May 6, 2019. (iv) The associated NAICS code is 325413 and the small business size standard is 1250 employees. No set-aside restriction is applicable. (v) The mission of the Tox21 group of NCATS at the National Institutes of Health (NIH) is to develop better toxicity assessment methods to quickly and efficiently test chemicals for their potential disrupt processes in the human body that may lead to negative health effects. Genotoxicity potential is a critical component within comprehensive toxicological profiles. Since P53 is often upregulated in cells subjected to physiological stresses and particularly to DNA damage, P53 activation can be used as an indicator of genotoxicity. Thus, identifying compounds which activate p53 is directly related to the Tox21 mission. At present, NCATS has completed the Tox21 10k screenings for p53-bla project in the absence of metabolism. This purchase-needed metabolic project is to identify the compounds that require metabolism to activate/inactivate p53. The assay using human liver microsomes will be one of the powerful methods for identifying these kind of compounds. The p53-bla with human liver microsomes assay has been optimized and validated in 1,536 well plate formats. (vi) Microsomes are subcellular fractions, which are derived from the endoplasmic reticulum of liver containing a rich variety of metabolic enzymes for assessing the in vitro metabolism of drug candidates. They are effective tools for the in vitro evaluation of metabolism, drug-drug interactions, hepatotoxicity, and transporter activity. Human liver microsomes are required by Tox21 groups to complete this project. "Mixed Gender Human Liver Microsomes" from the vendor will be prepared from fresh human liver tissue which ensures a higher retention of enzyme levels. This product has large pool of 50 donors with mixed gender that provides representation of population average of drug metabolism activity. Every donor used in the pool has a quality tested enzyme profile. Quantity: 300 vials (1mL each) of "Mixed Gender Human Liver Microsomes" (vii) Delivery shall be to: The National Center for Advancing Translational Sciences (NCATS) 9800 Medical Center Drive Rockville, MD 20850 Delivery shall be 4 weeks ARO. (viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix) Offers will be evaluated for technical criteria, price, and past performance. Technical criteria consist of matching the line items identified above. Technical and past performance, when combined, are significantly more important than price. OR The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: (i) technical evaluation criteria and/or technical capability of the item offered to meet the Government requirement (ii) price (iii) past performance [see FAR 13.106-2(b)(3)] Technical and past performance, when combined, are significantly more important than cost or price. (b) Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with offers. (xi) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. The following addendum applies: SOLICITATION PROVISIONS INCORPORATED BY REFERENCE (FEB 1998) This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a clause may be accessed electronically at these addresses: For FAR clauses: https://www.acquisition.gov/browsefar For HHSAR clauses: https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (end of clause) The following FAR provisions or clauses are incorporated by reference: 52.204-7, System for Award Management (Oct 2018) 52.204-13, System for Award Management Maintenance (Oct 2018) 52.204-16, Commercial and Entity Code Reporting (Jul 2016) 52.204-18, Commercial and Entity Code Maintenance (Jul 2016) 52.212-4(g), Invoice, is supplemented by the NIH Invoice and Payment Instructions (2/2014). (xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. 52.204-10 Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2018) (Pub. L. 109-282) (31 U.S.C. 6101 note). 52.219-28 Post Award Small Business Program Representation (Jul 2013) (15 U.S.C. 632(a)(2)) 52.222-3 Convict Labor (June 2003) 52.222-19 Child Labor-Cooperation With Authorities and Remedies (Jan 2018) 52.222-21 Prohibition of Segregated Facilities (Apr 2015) 52.222-26 Equal Opportunity (Sep 2016) 52.222-36 Equal Opportunity for Workers With Disabilities (Jul 2014) 52.222-50 Combating Trafficking in Persons (Mar 2015) 52.223-18 Encouraging Contractor Policies to Ban Text Messaging While Driving (Aug 2011) 52.225-1 (i), Buy American-Free Trade Agreements-Israeli Trade Act (May 2014) (41 U.S.C. chapter 83, 19 U.S.C. 3301 note, 19 U.S.C. 2112 note, 19 U.S.C. 3805 note, 19 U.S.C. 4001 note, Pub. L. 103-182, 108-77, 108-78, 108-286, 108-302, 109-53, 109-169, 109-283, 110-138, 112-41, 112-42, and 112-43. (ii) Alternate I (May 2014) of 52.225-3. 52.225-13 Restrictions on Certain Foreign Purchases (June 2008) (E.O.'s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury) 52.232-33 Payment by Electronic Funds Transfer-- System for Award Management (Jul. 2013) (xiii) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xiv) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xv) This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. In addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government whether to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered to determine whether to proceed on a non-competitive basis as indicated above, or to conduct a competitive procurement. All responses must be received by August 19th, 2019 at 11:00am, Eastern Standard Time and reference solicitation number 75N95019Q00306. Responses must be submitted electronically to Jessica Adams at jessica.adams@nih.gov. Fax responses will not be accepted. (xvi) The name and email address of the individual to contact for information regarding the solicitation: Jessica Adams at jessica.adams@nih.gov.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75N95019Q00306- Combined Synopsis
- Combined SynopsisCurrentAug 12, 2019
Mixed Gender Human Liver Microsomes for NCATS Tox21 program
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Redacted J&A posted in accordance with RFO 6.301 | - | Sole Source / J&A | Open |
See Soliciation Amendments 0001, 0002, and 0003. USAISR's Combat Casualty Care Research Team 1 (CRT-1) requires resupply of its Blood Donor Room on a reoccurring basis in order to satisfy research requirements for blood collection. USAISR currently has three Terumo Trima Accel Blood Collection Systems in operation. These units support numerous research protocols. Various collection sets are used to collect a variety of blood products from donors. The Trima instrument is FDA-approved, but only with the use of original manufacturer-supplied consumable products. These consumables are specific to the instrument and there are no generic substitute products available in the marketplace. Please note - This is a 100% set-aside for Service-Disabled Veteran-Owned Small Businesses. See attached complete solicitation for all requirement details and instructions to offerors. | - | Solicitation | 11/20/2026 |
DESCRIPTION This RFI is solely for information and planning purposes and does not constitute a solicitation or obligation on the part of the Government. Per FAR 15.201(e), responses to this notice are not considered offers, shall not be used as a proposal, and cannot be accepted by the Government to form a binding contract. Neither unsolicited proposals nor any other kinds of offers will be considered in response to this notice. No evaluation letters and/or results will be issued to the respondents; however, the Government does reserve the right to contact any respondent and/or respondent reference to obtain additional information. At this time, no solicitation exists; therefore, please do not request a copy of the solicitation. Any resulting procurement action will be the subject of a separate, future announcement. The information is provided for discussion purposes and any potential strategy for this acquisition may change prior to any solicitation release. The acquisition strategy, evaluation methodology, contract type, and any other acquisition decisions are to be determined. Background. The offeror shall provide to the Veterans Affairs Medical Health Care System at Baltimore VAMC all reagents and supplies for flow cytometry testing in the Hematology section of Pathology and Laboratory Medicine Service. The reagents/supplies will be used for CD4/CD8 count testing and the phenotyping of white blood cells in the leukemia and lymphoma assay using the Becton Dickinson FACSLyric. QC material and calibration material are used for the detection of voltages and spectral overlap to monitor optimal cytometer settings, checks, and track the daily performance. Performance Period: 12/03/2026 to 12/02/2027 Quantities are estimates: Item # Description Qty 643774 Anti-Kappa FITC TB28-2 ASR 4 642924 Anti-Lambda PE 1-55-2 ASR 4 341103 CD19 PE-Cy7 SJ25C1 ASR 4 340922 CD10 APC HI10a ASR 4 641405 CD20 APC-H7 L27 ASR 4 646852 CD38 V450 ASR 3 647450 CD45 V500-C ASR 4 663985 CD5 (L17F12) BV605 ASR 4 340918 FMC7 FITC ASR 4 340997 CD103 PE Ber-ACT8 ASR 2 659116 CD23 APC-R700 (EBVCS-5) ASR 3 655112 CD11c V450 ASR 3 340706 CD57 FITC HNK-1 ASR 3 340948 CD3 PerCP-Cy5.5 SK7 ASR 3 335804 CD2 PE-Cy7 L303.1 ASR 3 562660 Hu CD25 BV605 2A3 100Tst 3 659115 CD7 APC-R700 (M-T701) ASR 3 641409 CD8 APC-H7 SK1 ASR 3 651850 CD4 V450 (SK3) ASR 3 340688 Anti-HLA-DR FITC L243 (G46-6) ASR 3 644386 CD64 PE 10.1 ASR 3 338432 CD13 PE-Cy7 L138 ASR 3 340667 CD34 APC 8G12 ASR 3 659113 CD33 APC-R700 (P67-6) ASR 3 643077 CD14 APC-H7 MphiP9 ASR 3 663803 CD117 (104D2) BV605 ASR 3 657887 CD56 APC-R700 NCAM16.2 ASR 3 563826 Hu Alp Bta TCR APC T10B9.1A-31 100Tst 2 341635 CD30 PE Ber-H83 ASR 2 341097 CD138 PerCP-Cy5.5 MI15 ASR 2 655019 CD27 APC (L128) ASR 2 665134 CD81 (JS-81) BV605 ASR 2 656311 CD22 PerCP-Cy5.5 (S-HCL-1) ASR 3 663994 CD123 (9F5) APC-R700 ASR 2 649455 CD26 PE (L272) ASR 2 655434 TCR gamma/delta-1 PE-Cy7 (11F2) ASR 2 340655 Anti-MPO FITC 5B8 ASR 2 347209 Anti-TdT PE E17-1519 ASR 2 659114 CD34 APC-R700 (8G12) ASR 3 664538 CD22 (S-HCL-1) PE-Cy7 ASR 2 340653 CD79a APC HM47 ASR 2 341641 CD1a PE SK9 ASR 2 663196 CD158a (HP-3E4) PE ASR 2 663990 CD56 (NCAM16.2) BV605 ASR 2 644490 CD 16 V450 3G8 ASR 2 562361 Hu CD94 PerCP-CY5.5 HP-3D9 100Tst 2 562124 Hu CD200 PerCP-Cy5.5 MRC OX-104 50Tst 3 656152 CD36 FITC CLB-IVC7 ASR 2 562371 Hu CD 15 PE W6D3 100Tst 2 340936 CD11b APC D12 ASR 2 347213 CD34 PerCP-Cy5.5 8G12 ASR 2 340715 CD61 FITC RUU-PL7F12 ASR 2 340946 Glycophorin A PE GAR-2(HIR2) ASR 2 644490 CD 16 V450 3G8 ASR 2 662414 CST beads 150T IVD 2 342003 BD FACSFlow Sheath Fluid 20L 20 349202 BD FACS Lysing Solution 10X 100ML IVD 2 559925 7-AAD Staining Solution 2mL 3 563794 Brilliant Stain Buffer 5ml 6 554656 Stain Buffer FBS 500mL 20 552843 Ms Ig Kpa Comp Bead Set 6mL 1 555899 Lysing Buffer 10X Concentrate 100mL 8 340345 BD FACS Clean Solution 5L 1 562776 Ms CD140A PE APA5 50ug 3 340499 Multitest CD3/CD8/CD45/CD4 50 Tests IVD 30 662961 BD FC Beads 7-Color Kit (US-IVD) 1 349705 Multi-Check CD4 Low Ctrl 5X2.5mL US-IVD 6 349702 Multi-Check Control 5X2.5mL US-IVD 6 661624 BD FC Beads V500-C 1 661623 BD FC Beads V450 1 661626 BD FC Beads BV605 1 661621 BD FC Beads APC-H7 1 661625 BD FC Beads APC-R700 1 RESPONSES: Please include descriptive literature demonstrating the product meets or exceeds the brand name product specified above. Please provide any product solution or configuration so long as they are equivalent to the brand name product. Responses can include any additional product that may be beneficial. These items must be clearly identified by brand name and part number. PLEASE PROVIDE THE FOLLOWING ADDITIONAL INFORMATION: Full name and address of company DUNS number/ CAGE Code/ SAM UEI Business Size Manufacturer or Distributor If distributor, provide full name, business size, and address of manufacturer. Country of Origin designation for all products. Technical Literature that clearly shows product(s) are equivalent. Any additional product solution or configuration that would be beneficial to the functionality of the product line identified. Authorized Distributor Letter Certified by OEM with a current date. Although not required, vendors responding to this Sources Sought may also submit a Capabilities Statement. | - | Market Research | 11/12/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business. | - | Combined Synopsis | 11/05/2026 |
Please see attached Combined Synopsis/Solicitation. | - | Combined Synopsis | 11/16/2026 |
Additional Details
Solicitation Number
75N95019Q00306
Archive Date
Sep 3, 2019